Imfinzi(AstraZeneca)은 Locally Advanced Rectal Carcinoma 표적 항체로, Locally Advanced Rectal Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: binds to the PD-1 receptor. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 61% (ClinicalTrials.gov NCT02870920). 차별점: novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m.
Locally Advanced Rectal Carcinoma
Locally Advanced Rectal Carcinoma
Active
CAR-T cell and anticancer peptide synergy
humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluatio
novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m
binds to the PD-1 receptor
T cell activation
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
PD-L1 expression
escape detection by the immune system
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Imfinzi(AstraZeneca)은 Locally Advanced Rectal Carcinoma 표적 항체로, Locally Advanced Rectal Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: binds to the PD-1 receptor. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 61% (ClinicalTrials.gov NCT02870920). 차별점: novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m.
Locally Advanced Rectal Carcinoma
Locally Advanced Rectal Carcinoma
Active
CAR-T cell and anticancer peptide synergy
humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluatio
novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m
binds to the PD-1 receptor
T cell activation
DNA damage response (DDR) mutations and circulating tumor DNA (ctDNA) clearance emerged as promising biomarkers
PD-L1 expression
escape detection by the immune system
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.